Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)
Portfolio Pulse from Benzinga Insights
Fulcrum Therapeutics (NASDAQ:FULC) has received mixed analyst ratings over the past three months, with 4 analysts offering evaluations. The ratings include 2 bullish and 2 somewhat bullish, with a notable increase in the 12-month price target to an average of $15.25 from $13.50. Analysts from Goldman Sachs, RBC Capital, HC Wainwright & Co., and Piper Sandler have provided updates, with actions including announcements and raises in ratings and price targets. Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, has shown a revenue growth rate of 27.15% as of December 31, 2023, but faces challenges with a net margin of -2842.25% and below-average ROA.
May 13, 2024 | 9:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Fulcrum Therapeutics has received mixed reviews from analysts, with an updated average 12-month price target of $15.25, indicating a positive outlook on the stock's future performance despite its current financial challenges.
The mixed analyst ratings with a positive adjustment in the 12-month price target suggest a cautiously optimistic outlook for Fulcrum Therapeutics. The recent actions by analysts from reputable firms indicate a belief in the company's potential for growth, despite its current financial challenges such as a high net margin loss and below-average ROA. The increase in the average price target reflects an expectation of stock performance improvement, which could positively impact short-term investor sentiment and stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100